Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial : the OPuS‐2 study

  • Background: Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐2) evaluated the efficacy and safety of prophylactic avoralstat 300 or 500 mg compared with placebo. Methods: OPuS‐2 was a Phase 3, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Subjects were administered avoralstat 300 mg, avoralstat 500 mg, or placebo orally 3 times per day for 12 weeks. The primary efficacy endpoint was the angioedema attack rate based on adjudicator‐confirmed attacks. Results: A total of 110 subjects were randomized and dosed. The least squares (LS) mean attack rates per week were 0.589, 0.675, and 0.593 for subjects receiving avoralstat 500 mg, avoralstat 300 mg, and placebo, respectively. Overall, 1 subject in each of the avoralstat groups and no subjects in the placebo group were attack‐free during the 84‐day treatment period. The LS mean duration of all confirmed attacks was 25.4, 29.4, and 31.4 hours for the avoralstat 500 mg, avoralstat 300 mg, and placebo groups, respectively. Using the Angioedema Quality of Life Questionnaire (AE‐QoL), improved QoL was observed for the avoralstat 500 mg group compared with placebo. Avoralstat was generally safe and well tolerated. Conclusions: Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1‐INH‐HAE, it provided evidence of shortened angioedema episodes and improved QoL in the avoralstat 500 mg treatment group compared with placebo.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Marc A. Riedl, Emel Aygören-PürsünORCiDGND, James Baker, Henriette Farkas, John Anderson, Jonathan A. Bernstein, Laurence Bouillet, Paula Busse, Michael Manning, Markus Magerl, Mark Gompels, Aarn P. Huissoon, Hilary Longhurst, William Lumry, Bruce Ritchie, Ralph Shapiro, Daniel Soteres, Aleena Banerji, Mauro Cancian, Douglas T. Johnston, Timothy Craig, David Launay, Henry Li, Myron Liebhaber, Timothy Nickel, Jacob Offenberger, William Rae, Rik Schrijvers, Massimo Triggiani, H. James Wedner, Sylvia Dobo, Melanie Cornpropst, Desiree Clemons, Lei Fang, Phil Collis, William P. Sheridan, Marcus Maurer
URN:urn:nbn:de:hebis:30:3-508601
DOI:https://doi.org/10.1111/all.13466
ISSN:1398-9995
ISSN:0105-4538
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/29688579
Parent Title (English):Allergy
Publisher:Blackwell Munksgaard
Place of publication:Oxford
Contributor(s):Aubri Charboneau, Caren Carver
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/04/24
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2019/09/02
Tag:C1 inhibitor; hereditary angioedema; oral kallikrein inhibitor; prophylaxis
Volume:73
Issue:9
Page Number:10
First Page:1871
Last Page:1880
Note:
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
HeBIS-PPN:453725481
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0